High-dose ketoconazole therapy in prostatic cancer. A pilot study.
There may be contraindications to oestrogen therapy for prostatic carcinoma, and also patient objections to orchidectomy as a form of therapy. Ketoconazole, a systemic antifungal drug, was evaluated in a dosage of 200 mg 8-hourly given orally as an alternative method of lowering serum testosterone levels. Nineteen patients were studied; 1 was withdrawn because of nausea and vomiting. Only 6 patients (33,3%) had serum testosterone levels in the castrate range after 7 days. It seems that higher doses may be needed to keep testosterone levels consistently low.
D000284:Administration, Oral; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D010865:Pilot Projects; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D007654:Ketoconazole